Alexa Meara, MD
Rheumatology · Columbus, OHNPI 1063670693
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $287,776 of the $426,214 with a category attached, or 67.5%. 19 manufacturers reported payments, led by AbbVie at 29.2% of the total. Reporting peaked in 2024 at $119,545 and has fallen 52.9% since, to $56,289 in 2025. Among rheumatology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 528 payments — averaging $807.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$124K
- Sanofi$109K
- Amgen$75K
- AstraZeneca$52K
- Aurinia Pharma U.S., Inc.$34K
- GSK$14K
- plus $18K from 13 others
Across 16 payments — averaging $3401.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$43K
- Genentech, Inc.$9K
- AbbVie$2K
What the payments were for
- Consulting fees$75,39518%
- Speaking & faculty fees$287,77668%
- Travel & lodging$51,00712%
- Food & beverage$12,0363%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 162 | $124,464 |
| Sanofi | 85 | $108,920 |
| Amgen | 101 | $75,192 |
| AstraZeneca(2 entities) | 53 | $51,987 |
| Aurinia Pharma U.S., Inc. | 50 | $33,553 |
| GSK | 3 | $14,450 |
| Johnson & Johnson(2 entities) | 21 | $11,746 |
| Sobi, Inc | 13 | $4,234 |
| Novartis | 7 | $447 |
| UCB, Inc. | 8 | $323 |
| Mallinckrodt Hospital Products Inc. | 16 | $310 |
| BD | 1 | $274 |
| Genentech, Inc. | 2 | $139 |
| E.r. Squibb & Sons, L.L.C. | 1 | $63 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| Tonix Medicines, Inc. | 1 | $30 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$426,214 in reported general payments places this provider in the 95th percentile of 255 rheumatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KevzaraSarilumab | 12 | $49,318 |
| Hydroxychloroquine Sulfate | 344 | $9,912 |
| Budesonide EcBudesonide | 11 | $7,103 |
| Celecoxib | 19 | $4,944 |
| Prednisone | 265 | $1,638 |
| Duloxetine Hcl | 70 | $1,338 |
| Gabapentin | 51 | $1,070 |
| Mycophenolate Mofetil | 19 | $801 |
| Methylprednisolone | 16 | $789 |
| Pregabalin | 32 | $729 |
| Leflunomide | 20 | $437 |
| MethotrexateMethotrexate Sodium | 12 | $314 |
| Diclofenac Sodium | 11 | $287 |
| Tramadol Hcl | 30 | $267 |
| Triamcinolone Acetonide | 15 | $252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiKevzara | $108,920 | $49,31812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 rheumatology providers in Ohio.
Other rheumatology in Columbus
- Kevin SchlesselColumbus$63K
- Jacob SeymourColumbus$27K
- Ali AjamColumbus$24K
- Heather LakeColumbus$13K
- Matthew MundwilerColumbus$11K
- Marc AntonchakColumbus$10K
- Leonard CalabreseCleveland$1.9M
- Gregory DelorenzoCincinnati$1.3M
- Chad DealCleveland$375K
- David MandelMayfield Village$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.